Article Text

Download PDFPDF
Is HBV RNA a valid marker for predicting sustained viral response for nucleoside analogue cessation?
  1. Babu Lal Meena,
  2. Madhumita Premkumar,
  3. Akash Roy,
  4. Virendra Singh
  1. Hepatology, PGIMER, Chandigarh, India
  1. Correspondence to Professor Virendra Singh, Hepatology, PGIMER, Chandigarh, Chandigarh, India; virendrasingh100{at}

Statistics from

We read with great interest the recent article by Seto et al in which the authors aimed to explore the feasibility and potential role of HBV RNA, hepatitis B core-related antigen (HBcrAg) and quantitative hepatitis B surface antigen (HBsAg) in identifying Asian patients with chronic hepatitis B suitable for the cessation of treatment.1 The study is well designed, and the results offer insight into the treatment in hepatitis B. However, certain key issues need to be highlighted.

The virological relapse was 36.6%, even if HBV RNA was not detected. This is in discordance to Fan et al, who suggested a lower virological relapse (8%) in patients who are HBV RNA negative versus higher relapse rates if RNA was positive (33.3%).2 The current study does not have clear validation for using …

View Full Text


  • Contributors BLM: writing; MP: writing and critical revision; AR: writing and critical revision; VS: critical revision.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

  • Provenance and peer review Not commissioned; internally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.